Press releases Archives - Page 5 of 12

Press releases

Mar

2025

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Hamlet Biopharma

Vid extra bolagsstämma i Hamlet BioPharma AB (publ), org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) idag den 11 mars 2025 fattades bland ann...

Feb

2025

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

Hamlet Biopharma

Press releases

Med anledning av Pressmeddelanden och nyheter bjuder Hamlet BioPharma in till investerarmöte fredagen den 21 februari, 2025, klockan 12.00. Bolaget k...

Feb

2025

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

Hamlet Biopharma

Press releases

Aktieägarna i Hamlet BioPharma AB (publ) (”Hamlet BioPharma” eller ”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma tisdagen den ...

Feb

2025

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies

Hamlet Biopharma

Press releases

Hamlet BioPharma AB (“Hamlet BioPharma” or the “Company”), an innovative pharmaceutical company that develops new therapies a...

Feb

2025

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Hamlet Biopharma

Press releases

Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years’ experi...

Feb

2025

Catharina Svanborg appointed as CEO and assumes the position immediately, board member Magnus Nylén acting Chairman

Hamlet Biopharma

Press releases

The Board of Hamlet BioPharma has today decided to appoint Catharina Svanborg as CEO. Catharina immediately assumes the CEO role and continues as a B...

Feb

2025

Q2 Interim Report October 2024 – December 2024

Hamlet Biopharma

Financial, Press releases

...

Feb

2025

Hamlet BioPharma bjuder in till pressträff den 13 februari med anledning av Q2 rapport

Hamlet Biopharma

Press releases

Med anledning av bolagets kvartalsrapport 2 för 2024/2025, bjuder Hamlet BioPharma in till en livesänd digital pressträff torsdagen den 13 februari, 2...

Feb

2025

Presentation den 6.2.25 på Vetenskapsrådets konferens kring Antibiotikaresistens

Hamlet Biopharma

Press releases

Hamlet BioPharma AB, det innovativa läkemedelsbolaget, som utvecklar nya terapier mot cancer och infektioner, meddelar två viktiga händelser. Den 6 f...

Jan

2025

Invitation to monthly digital events and presentations of quarterly reports

Hamlet Biopharma

Press releases

Hamlet BioPharma is pleased to announce the continuation of the digital event series in the spring of 2025. These events provide participants a valuab...

« Previous

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

Hamlet BioPharma.

Press releases

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Catharina Svanborg appointed as CEO and assumes the position immediately, board member Magnus Nylén acting Chairman

Q2 Interim Report October 2024 – December 2024

Hamlet BioPharma bjuder in till pressträff den 13 februari med anledning av Q2 rapport

Presentation den 6.2.25 på Vetenskapsrådets konferens kring Antibiotikaresistens

Invitation to monthly digital events and presentations of quarterly reports

Pressmeddelande – Lund 4 december, 2025 – Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Nyhetsbrev – FDA ger Hamlet BioPharma pivotal status för avgörande Fas III studie i blåscancer

Q1 Interim Report July – September 2025

Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

Press releases

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Hamlet BioPharma bjuder in till investerarmöte den 21 februari

Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value ​​for both companies

Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd

Catharina Svanborg appointed as CEO and assumes the position immediately, board member Magnus Nylén acting Chairman

Q2 Interim Report October 2024 – December 2024

Hamlet BioPharma bjuder in till pressträff den 13 februari med anledning av Q2 rapport

Presentation den 6.2.25 på Vetenskapsrådets konferens kring Antibiotikaresistens

Invitation to monthly digital events and presentations of quarterly reports

Pressmeddelande – Lund 4 december, 2025 – Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Nyhetsbrev – FDA ger Hamlet BioPharma pivotal status för avgörande Fas III studie i blåscancer

Q1 Interim Report July – September 2025

Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies